Treace Medical Concepts Reports Q3 2026 Results, Updates Revenue Guidance
Treace reported a net loss of $12.6 million, or $0.19 per share, versus $16.3 million, or $0.26 per share, a year earlier. Adjusted EBITDA was $0.3 million, compared with $(2.6) million. The company narrowed its 2026 revenue guidance to $206 million-$210 million from $204 million-$212 million.
Treace Medical Concepts, Inc. reported a third quarter 2026 net loss of $12.6 million, or $0.19 per share, an improvement from the $16.3 million net loss, or $0.26 per share, reported in the same period of 2025. Adjusted EBITDA for the quarter was $0.3 million, compared to $(2.6) million in the prior year period. The company also updated its full-year 2026 revenue guidance to a range of $206 million to $210 million, adjusted from the previous range of $204 million to $212 million.
Additionally, the company reported a 53% reduction in year-to-date cash usage compared to the same period in 2025 and noted that total operating expenses decreased by 10% to $49.9 million.